Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$8.67 USD
-0.48 (-5.25%)
Updated May 17, 2024 04:00 PM ET
After-Market: $8.69 +0.02 (0.23%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRCA 8.67 -0.48(-5.25%)
Will VRCA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VRCA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRCA
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates
VRCA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates
Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?
Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?
Other News for VRCA
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Analysts Offer Insights on Healthcare Companies: Xtant Medical Holdings (XTNT) and Verrica Pharmaceuticals (VRCA)
Biotech Alert: Searches spiking for these stocks today
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts